4SC AG has licensed, on an exclusive basis, its investigational pan-histone deacetylase (HDAC) inhibitor for oncology, resminostat, to Yakult Honsha Co Ltd for development and commercialisation in Japan. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
